PTO- 1478 |
Approved for use through 09/30/2021. OMB 0651-0009 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Serial Number: 97052261 |
Filing Date: 09/29/2021 |
Input Field |
Entered |
TEAS Plus | YES |
---|---|
MARK INFORMATION | |
*MARK | AREXVY |
*STANDARD CHARACTERS | YES |
USPTO-GENERATED IMAGE | YES |
LITERAL ELEMENT | AREXVY |
*MARK STATEMENT | The mark consists of standard characters, without claim to any particular font style, size, or color. |
REGISTER | Principal |
APPLICANT INFORMATION | |
*OWNER OF MARK | GlaxoSmithKline Biologicals SA |
*MAILING ADDRESS | Rue de l'Institut 89 |
*CITY | Rixensart |
*COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | Belgium |
*ZIP/POSTAL CODE (Required for U.S. and certain international addresses) |
B-1330 |
*EMAIL ADDRESS | XXXX |
LEGAL ENTITY INFORMATION | |
*TYPE | private company limited by shares (prc) |
* STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY WHERE LEGALLY ORGANIZED | Belgium |
GOODS AND/OR SERVICES AND BASIS INFORMATION | |
*INTERNATIONAL CLASS | 005 |
*IDENTIFICATION | Vaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders |
*FILING BASIS | SECTION 1(b) |
*FILING BASIS | SECTION 44(d) |
*FOREIGN APPLICATION NUMBER | 3662314 |
*FOREIGN APPLICATION COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United Kingdom |
*FOREIGN FILING DATE | 06/30/2021 |
INTENT TO PERFECT 44(d) |
At this time, the applicant has another basis for registration (Section 1(a) or Section 1(b)) and does NOT intend to rely on Section 44(e) as the basis for registration, but is only asserting a valid claim of priority. |
ADDITIONAL STATEMENTS SECTION | |
*TRANSLATION (if applicable) |
|
*TRANSLITERATION (if applicable) |
|
*CLAIMED PRIOR REGISTRATION (if applicable) |
|
*CONSENT (NAME/LIKENESS) (if applicable) |
|
*CONCURRENT USE CLAIM (if applicable) |
|
SIGNIFICANCE OF MARK | The word(s) AREXVY has no meaning in a foreign language. |
ATTORNEY INFORMATION | |
NAME | Christopher M. Hanes |
ATTORNEY DOCKET NUMBER | 84025198 |
ATTORNEY BAR MEMBERSHIP NUMBER | XXX |
YEAR OF ADMISSION | XXXX |
U.S. STATE/ COMMONWEALTH/ TERRITORY | XX |
FIRM NAME | GSK |
INTERNAL ADDRESS | 5.5A, LBP |
STREET | 5 Moore Drive |
CITY | Research Triangle Park |
STATE | North Carolina |
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
ZIP/POSTAL CODE | 27709 |
PHONE | 919-450-7041 |
FAX | 919-315-3023 |
EMAIL ADDRESS | trademarks@gsk.com |
OTHER APPOINTED ATTORNEY | Arrielle S. Millstein |
CORRESPONDENCE INFORMATION | |
NAME | Christopher M. Hanes |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | trademarks@gsk.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | NOT PROVIDED |
FEE INFORMATION | |
APPLICATION FILING OPTION | TEAS Plus |
NUMBER OF CLASSES | 1 |
APPLICATION FOR REGISTRATION PER CLASS | 250 |
*TOTAL FEES DUE | 250 |
*TOTAL FEES PAID | 250 |
SIGNATURE INFORMATION | |
* SIGNATURE | /Christopher M. Hanes/ |
* SIGNATORY'S NAME | Christopher M. Hanes |
* SIGNATORY'S POSITION | Trademark Counsel, NC bar member |
SIGNATORY'S PHONE NUMBER | 919-450-7041 |
* DATE SIGNED | 09/29/2021 |
SIGNATURE METHOD | Sent to third party for signature |
PTO- 1478 |
Approved for use through 09/30/2021. OMB 0651-0009 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Serial Number: 97052261 |
Filing Date: 09/29/2021 |
The applicant's current Correspondence Information: |
Christopher M. Hanes |
PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@gsk.com SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS). |
|
|